Biogen Inc. (BIIB) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $190.56, but acceptable to hold if already in. Reasons: Thin upside margin: 3.6%; Consecutive earnings misses (2).
Biogen is a global biopharmaceutical company focused on neurology and rare diseases, commercializing MS therapies (VUMERITY, TYSABRI, AVONEX, PLEGRIDY), SPINRAZA for SMA, SKYCLARYS for Friedreich's ataxia, and QALSODY for ALS, with Eisai collaboration on LEQEMBI for Alzheimer's.... Read more
Hold if already holding. Not a fresh buy at $190.56, but acceptable to hold if already in. Reasons: Thin upside margin: 3.6%; Consecutive earnings misses (2). Chart setup: RSI 45 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.6/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news boost analyst 0.80, earnings proximity 72d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Biogen Inc.
Latest news
- Biogen Inc. (BIIB.US) 1Q Earnings and Revenue Beat Forecasts - AASTOCKS.com — AASTOCKS.com positive
- Is It Time To Reassess Biogen (BIIB) After Its Strong One Year Share Price Rally - Yahoo Finance — Yahoo Finance positive
- Biogen Had A Nearly Perfect Sales Sweep, But One Beat Really Stood Out - Investor's Business Daily — Investor's Business Daily positive
- Biogen (BIIB) Lowers 2026 Earnings Guidance Despite Q1 Sales Gro - GuruFocus — GuruFocus negative
- Biogen (BIIB) Reports Strong Q1 Earnings, Raises 2026 EPS Guidan - GuruFocus — GuruFocus positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductTYSABRI and SPINRAZA10-K Item 1: 'Product sales for TYSABRI and SPINRAZA each accounted for more than 10.0% of our total revenue for the years ended December 31, 2025, 2024 and 2023'
Material Events(8-K, last 90d)
- 2026-03-11Item 5.02LOWChief Legal Officer Susan H. Alexander will depart Biogen effective end of May 2026. Company has initiated a search for the next CLO. No reason cited for departure.SEC filing →
- 2026-02-11Item 5.02LOWBoard Chair Caroline Dorsa will not stand for re-election at 2026 Annual Meeting. Decision not due to any disagreement with Board or Company. Dr. Maria C. Friere elected as Chair effective after the Annual Meeting.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $190.56, but acceptable to hold if already in. Reasons: Thin upside margin: 3.6%; Consecutive earnings misses (2). Chart setup: RSI 45 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $197.34 (+3.6%), stop $179.26 (−6.3%), A.R:R 0.6:1. Score 5.6/10, moderate confidence.
Take-profit target: $197.34 (+3.6% upside). Target $197.34 (+3.6%), stop $179.26 (−6.3%), A.R:R 0.6:1. Stop-loss: $179.26.
Thin upside margin: 3.6%; Consecutive earnings misses (2); Negative momentum.
Biogen Inc. trades at a P/E of 20.6 (forward 11.6). TrendMatrix value score: 6.3/10. Verdict: Hold.
43 analysts cover BIIB with a consensus score of 3.7/5. Average price target: $219.
What does Biogen Inc. do?Biogen is a global biopharmaceutical company focused on neurology and rare diseases, commercializing MS therapies...
Biogen is a global biopharmaceutical company focused on neurology and rare diseases, commercializing MS therapies (VUMERITY, TYSABRI, AVONEX, PLEGRIDY), SPINRAZA for SMA, SKYCLARYS for Friedreich's ataxia, and QALSODY for ALS, with Eisai collaboration on LEQEMBI for Alzheimer's. Revenue comes from product sales and anti-CD20 program royalties from Genentech; TYSABRI and SPINRAZA each exceeded 10% of total revenue in 2025.